Morgan Stanley
VRPX

Morgan Stanley’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Morgan Stanley’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20
Closed -$190 – 8344
2024
Q4 		$190 Buy
20
+19
+1,900% +$253 ﹤0.01% 7418
2024
Q3 		$10 Hold
1
– – ﹤0.01% 7869
2024
Q2 		$8 Hold
1
– – ﹤0.01% 7793
2024
Q1 		$64 Hold
1
– – ﹤0.01% 7437
2023
Q4 		$96 Hold
1
– – ﹤0.01% 7485
2023
Q3 		$120 Hold
1
– – ﹤0.01% 7431
2023
Q2 		$162 Hold
1
– – ﹤0.01% 7467
2023
Q1 		$118 Sell
1
-3
-75% -$670 ﹤0.01% 7559
2022
Q4 		$669 Hold
4
– – ﹤0.01% 7527
2022
Q3 		$1K Sell
4
-68
-94% -$24.5K ﹤0.01% 7631
2022
Q2 		$30K Sell
72
-242
-77% -$99.2K ﹤0.01% 6841
2022
Q1 		$174K Buy
314
+294
+1,470% +$171K ﹤0.01% 5997
2021
Q4 		$16K Buy
20
+11
+122% +$11.3K ﹤0.01% 7310
2021
Q3 		$11K Buy
9
+6
+200% +$12.6K ﹤0.01% 7296
2021
Q2 		$3K Buy
+3
New +$3.22K ﹤0.01% 7498

Other funds holding VRPX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VWM
Vermillion Wealth Management Rosemount, Minnesota $427M AUM 12.63% 1-Year Est. Return

Morgan Stanley's VRPX Position: Q1 2025 in Review

Morgan Stanley sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2025, closing a stake of 20 shares — an estimated $190 sold.

Morgan Stanley first reported a position in VRPX in Q2 2021 and held it in 15 quarters. The position peaked at $174K in Q1 2022. 7 funds tracked by Wall St. Rank hold VRPX as of Q1 2025.

  • Morgan Stanley reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 20 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $190.
  • Morgan Stanley first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
  • Morgan Stanley's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $174K in Q1 2022.
  • 7 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.